SREBF1 and Insulin resistance: Antrodan elevated the level of adiponectin (Figure 3) and suppressed that of PPARγ and SREBP-1c, thereby inhibiting the lipid biosynthesis and promoting obese- and steatohepatitis-associated insulin resistance.